Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Vanguard Total Stock Mkt Idx Inv

Vanguard Institutional 500 Index Trust

Vanguard Institutional Index I

Vanguard PRIMECAP Inv

Dodge & Cox Stock I

Capital Group Fundamental Invtrs Comp

American Funds Fundamental Invs A

Pacer US Cash Cows 100 ETF

State St S&P 500® Indx SL Cl III

Vanguard High Dividend Yield ETF

American Funds American Mutual A

Capital Group American Mutual Comp

Schwab US Dividend Equity ETF™

SPDR® S&P 500® ETF Trust

Fidelity 500 Index

iShares Core S&P 500 ETF

Vanguard Value Index Inv

The Health Care Select Sector SPDR® ETF

JPMorgan Equity Income I

JPM US Equity Income-Composite

Vanguard Group Inc

BlackRock Inc

PRIMECAP Management Company

Bank of New York Mellon Corp

Northern Trust Corp

T. Rowe Price Associates, Inc.

Ameriprise Financial Inc

Legal & General Group PLC

UBS Asset Mgmt Americas Inc

Bank of America Corp

Amvescap Plc.

Dodge & Cox

State Street Corp

JPMorgan Chase & Co

Charles Schwab Investment Management Inc

FMR Inc

Geode Capital Management, LLC

Capital Research & Mgmt Co - Division 3

NORGES BANK

Morgan Stanley - Brokerage Accounts

Bristol-Myers Squibb Company

Dr. Christopher S. Boerner Ph.D.

CEO & Chairman

Mr. David V. Elkins

Executive VP & CFO

Ms. Sandra  Leung Esq.

Executive VP & General Counsel

Mr. Samit  Hirawat M.D.

Executive VP, Chief Medical Officer & Head of Development

Mr. Greg  Meyers

Executive VP and Chief Digital & Technology Officer

Mr. Timothy  Power

VP & Head of Investor Relations

Ms. Kimberly M. Jablonski

Chief Compliance & Ethics Officer

Ms. Ahn Amanda Poole

Executive Vice President & Chief Human Resources Officer

Dr. Joseph J. Eiden Jr.

Head of Medical Affairs

Mr. Adam  Lenkowsky

Executive VP, Chief Commercialization Officer & Head of U.S. Oncology

BMY's next earnings is on February 6, 2025 (Before Market Open)

BMY's latest dividend is 0.6 USD on July 5, 2024

Bristol-Myers Squibb Company (BMY) Stock Analysis, Discussion Forum and Financial Metrics - NYSE Exchange

Bristol-Myers Squibb Company (BMY) Earnings Report Date and History | NYSE

BMY's next earnings is on February 6, 2025 (Before Market Open)

When is the earnings report for BMY?

BMY Earnings History

BMY's latest dividend is 0.6 USD on July 5, 2024

BMY Stock Discussion Forum and Message Board

News for NYSE: BMY